Company intelligence / Profile preview
MEI Pharma
San Diego, California, United Statesmeipharma.com ↗
- Ownership
- Public · MEIP
- Development stage
- Other
01
Overview
MEI Pharma’s two main clinical-stage assets are voruciclib and ME-344. Voruciclib, an oral CDK9 inhibitor, has shown anti-leukemic activity in heavily pretreated AML patients when combined with venetoclax; no dose-limiting toxicities or overlapping toxicity observed to date. Expansion cohorts are enrolling and a Phase 3 registration trial could begin in late 2026 if data remain positive. ME-344, a mitochondrial OXPHOS inhibitor, demonstrated biological activity in combination with bevacizumab in solid tumors such as HER2-negative breast cancer and metastatic colorectal cancer. A new formulation of ME-344 is being developed to improve efficacy and patient convenience.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed recently; historically has engaged in strategic partnerships and outlicensing but none currently highlighted.
Beyond the preview
Go deeper on MEI Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEI Pharma.